How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

The maker of Claude wants AI labs, including itself, to prepare for a coordinated slowdown if models begin building their own ...

A decision tree regression system incorporates a set of if-then rules to predict a single numeric value. Decision tree regression is rarely used by itself because it overfits the training data, and so ...

Abstract: Differential dynamic programming (DDP) is a widely used trajectory optimization technique that addresses nonlinear optimal control problems, and can readily handle nonlinear cost functions.

Welcome everybody to Recursion's Earnings Call. I'm Chris Gibson, Co-Founder and CEO, and I'm excited to take you through Recursions 2024, 2025 and the time ahead. So with that we'll jump into the ...

Los Angeles—Artificial intelligence (AI)-based drug discovery continues to tout accelerated timelines and novel and effective treatments, yet today’s clinical success rates remain at a low 10%. On ...

The artificial intelligence (AI) revolution continues to tout developing drugs faster and at lower cost, but are we there yet? On October 2nd, the FDA cleared an investigational new drug (IND) ...

Training spiking recurrent neural networks on neuronal recordings or behavioral tasks has become a popular way to study computations performed by the nervous system. As the size and complexity of ...

Ariella Brown has written about technology and marketing, covering everything from analytics to virtual reality since 2010. Before that she earned a PhD in English,… To better understand this distinct ...